Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
24.44 USD +1.28% Intraday chart for Arrowhead Pharmaceuticals, Inc. +10.49% -20.13%
May. 03 Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug MT
Apr. 24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
MT
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
BU
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
BU
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
BU
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
CI
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
BU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BU
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
BU
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran
CI
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
MT
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation
PU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
CI
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
BU
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
CI
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
CI
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. News Arrowhead Pharmaceuticals, Inc.